Şekuri C.Çam F.S.Tengiz I.Ercan E.Bayturan Ö.Berdeli A.2024-07-222024-07-22200613028723http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19526Objective: Platelet-activating factor (PAF) is a phospholipid with multiple actions that is involved in inflammatory diseases as well as in atherogenesis. It is inactivated by a plasma enzyme, PAF-acetylhydrolase (PAF-AH). Deficiency of this enzyme in plasma is caused by a missense mutation in the gene (G994T). The aim of this study was to investigate association of this mutation with premature coronary artery disease (CAD). Methods: One hundred and fifteen unrelated Turkish patients with a diagnosis of premature CAD and 128 unrelated healthy subjects were enrolled in this study. Genotyping was performed by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). Results: The prevalence of the G994T mutation in the patients was 2.60 % (heterozygote), and 0 % in the controls. There was no significant difference in allele frequency and genotype distribution among the study groups. Conclusion: The G9943T mutation in the plasma PAF acetylhydrola se gene is not associated with premature CAD in Turkish subjects.English1-Alkyl-2-acetylglycerophosphocholine EsteraseCase-Control StudiesCoronary ArteriosclerosisEuropean Continental Ancestry GroupFemaleHumansMaleMiddle AgedMutationPolymerase Chain ReactionPolymorphism, GeneticPolymorphism, Restriction Fragment LengthPrevalenceTurkey1 alkyl 2 acetylglycerophosphocholine esterasecholesterolDNA fragmentgenomic DNAhigh density lipoprotein cholesterollow density lipoprotein cholesteroltriacylglyceroladultarticlebody masscontrolled studycoronary artery diseasecoronary riskdiabetes mellitusDNA polymorphismfamily historyfemalegene frequencygene mutationgenetic associationgenotypeheterozygosityhumanhypertensionmajor clinical studymalepolymerase chain reactionprevalenceprotein blood levelrestriction fragment length polymorphismsmoking habitTurkey (republic)vascular diseaseArticle